# 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250 (317) 521 - 3831

Contact Person: Kathie J. Goodwin

Date Prepared: August $2 4 ^ { \mathfrak { t h } }$ , 2009

# Device Name

Proprietary names: COBAS INTEGRA Glucose HK Gen. 3 Assay

Common names: Glucose HK Gen. 3

Classification names: Glucose Test System

Regulation Number: 21 CFR 862.1345

Product codes: CFR

# Device Description

The cassette COBAS INTEGRA Glucose HK Gen. 3 contains an in vitro diagnostic reagent system intended for use on COBAS INTEGRA SYSTEMS for the quantitative determination of glucose in serum, plasma, urine, and cerebrospinal fluid (CSF).

The test principle is an enzymatic reference method with hexokinase.

# Intended use

In vio et r the quantiative determnation glucosen eu, plaa, urine and cerebrospinal fluid (CSF).

# Indications for Use

Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes melltus, neonatal hypoglycemia, idiopathic hypoglycemia and pancreatic islet cell tumors.

# Glucose HK Gen. 3 Stat Assay

The table below indicates the similarities between the modified COBAS INTEGRA Glucose HK Gen. 3 test and its predicate device COBAS INTEGRA Glucose HK Gen. 3, K061048.

Substantial equivalence   
Substantial equivalencecomparison   

<table><tr><td rowspan=1 colspan=1>Compalison</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>COBAS INTEGRA Glucose Gen. 3AssaySerum/Plasma Application</td><td rowspan=1 colspan=1>Predicate Device: COBASINTEGRA Glucose Gen. 3 AssaySerum/Plasma Application(K061048)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>In vitro test for the quantitativedetermination of glucose in serum,plasma, urine, and cerebrospinal fluid(CSF) on COBAS INTEGRAsystems.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Enzymatic reference method withHexokinase</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>SerumPlasma: Li-heparin, K2-EDTA, K3-EDTA and fluoride plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Calibrator f.a.s.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationFrequency</td><td rowspan=1 colspan=1>Each lot and as required followingquality control procedures</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Precinorm U or Precinorm U PlusAndPrecipath U or Precipath U Plus</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent Stability</td><td rowspan=1 colspan=1>Shelf life at 2 to 8°CIntegra 400/400 Plus: On-board in useat 10-15°C for 8 weeksIntegra 800: On-board in use at 8°Cfor 8 weeks</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>Regular Applications:4.32 - 720 mg/dLStat Applications:4.32 - 541 mg/dL</td><td rowspan=1 colspan=1>Regular Applications:2.16 - 720 mg/dL</td></tr></table>

# Glucose HK Gen. 3 Stat Assay

Substantial equivalence - comparison

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Level I</td><td rowspan=1 colspan=1>80.7</td><td rowspan=1 colspan=1>0.41</td></tr><tr><td rowspan=1 colspan=1>Level II</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>0.47</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>HS1</td><td rowspan=1 colspan=1>64.3</td><td rowspan=1 colspan=1>1.26</td></tr><tr><td rowspan=1 colspan=1>HS2</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>1.41</td></tr><tr><td rowspan=1 colspan=1>HS3</td><td rowspan=1 colspan=1>665</td><td rowspan=1 colspan=1>1.32</td></tr><tr><td rowspan=1 colspan=1>PNU</td><td rowspan=1 colspan=1>90.8</td><td rowspan=1 colspan=1>1.24</td></tr><tr><td rowspan=1 colspan=1>PPU</td><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=1>1.21</td></tr></table>

Between Run   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Level I</td><td rowspan=1 colspan=1>80.0</td><td rowspan=1 colspan=1>1.09</td></tr><tr><td rowspan=1 colspan=1>Level II</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>0.90</td></tr></table>

Serum - Stat Application: Repeatability (Within-Run Precision)   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>HS1</td><td rowspan=1 colspan=1>64.7</td><td rowspan=1 colspan=1>0.61</td></tr><tr><td rowspan=1 colspan=1>HS2</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>0.69</td></tr><tr><td rowspan=1 colspan=1>HS3</td><td rowspan=1 colspan=1>487</td><td rowspan=1 colspan=1>0.74</td></tr><tr><td rowspan=1 colspan=1>PNU</td><td rowspan=1 colspan=1>91.4</td><td rowspan=1 colspan=1>0.58</td></tr><tr><td rowspan=1 colspan=1>PPU</td><td rowspan=1 colspan=1>249</td><td rowspan=1 colspan=1>0.57</td></tr></table>

Intermediate (Between Run Precision)   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>HS1</td><td rowspan=1 colspan=1>64.7</td><td rowspan=1 colspan=1>1.08</td></tr><tr><td rowspan=1 colspan=1>HS2</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>1.40</td></tr><tr><td rowspan=1 colspan=1>HS3</td><td rowspan=1 colspan=1>487</td><td rowspan=1 colspan=1>1.10</td></tr><tr><td rowspan=1 colspan=1>PNU</td><td rowspan=1 colspan=1>91.4</td><td rowspan=1 colspan=1>1.15</td></tr><tr><td rowspan=1 colspan=1>PPU</td><td rowspan=1 colspan=1>249</td><td rowspan=1 colspan=1>1.07</td></tr></table>

Substantial

<table><tr><td rowspan=1 colspan=11>equivalence-comparison</td><td></td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=7>COBAS INTEGRA Glucose Gen. 3AssaySerum/Plasma Application</td><td rowspan=1 colspan=4>Predicate Device: COBASINTEGRA Glucose Gen. 3 AssaySeruim/Plasma Application(K061048)</td></tr><tr><td rowspan=33 colspan=1>Precision - Urine</td><td rowspan=1 colspan=7>Urine - Regular Application:Repeatability (Within-Run Precision)</td><td rowspan=1 colspan=4>Urine:Within-Run Precision</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>CV (%)</td><td rowspan=1 colspan=3>−</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=4 colspan=1></td></tr><tr><td rowspan=2 colspan=1>HS1</td><td rowspan=2 colspan=1>8.65</td><td rowspan=2 colspan=2>2.28</td><td rowspan=2 colspan=2></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>Level I</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>1.35</td></tr><tr><td rowspan=1 colspan=1>HS2</td><td rowspan=1 colspan=1>17.3</td><td rowspan=1 colspan=2>1.05</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level II</td><td rowspan=1 colspan=1>43.6</td><td rowspan=1 colspan=1>0.64</td></tr><tr><td rowspan=1 colspan=1>HS3</td><td rowspan=1 colspan=1>672</td><td rowspan=1 colspan=2>0.53</td><td rowspan=1 colspan=2></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=3 colspan=1>PNU</td><td rowspan=3 colspan=1>90.8</td><td rowspan=3 colspan=2>0.58</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=4 colspan=7>Between Run</td></tr><tr></tr><tr><td rowspan=1 colspan=1>PPU</td><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=2>0.59</td></tr><tr><td rowspan=1 colspan=7>Intermediate (Between Run Precision)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>CV (%)</td><td rowspan=1 colspan=3>−</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=5 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HS1</td><td rowspan=1 colspan=1>8.65</td><td rowspan=1 colspan=2>2.83</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level I</td><td rowspan=1 colspan=2>15.1</td></tr><tr><td rowspan=3 colspan=1>HS2</td><td rowspan=3 colspan=1>17.3</td><td rowspan=3 colspan=2>1.37</td><td rowspan=3 colspan=2></td><td rowspan=1 colspan=2></td><td></td><td></td><td></td></tr><tr><td rowspan=2 colspan=2></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level II</td><td rowspan=1 colspan=1>43.8</td><td rowspan=1 colspan=1>0.83</td></tr><tr><td rowspan=17 colspan=11>HS3      672          1.01PNU     90.8          1.24PPU     247          1.21Serum - Stat Application:Repeatability (Within-Run Precision)Sample    Mean     CV (%)(mg/dL)HS1      8.58         2.71HS2      17.4         1.16HS3      476          0.64PNU     91.4         0.58PPU     249         0.57Intermediate (Between Run Precision)Sample     Mean     CV (%)(mg/dL)HS1      8.58         3.20HS2      17.4          1.65HS3     476          1.09PNU     91.4         1.15PPU     249          1.07</td><td rowspan=1 colspan=1>HS3</td></tr><tr><td rowspan=2 colspan=1>PNU</td><td rowspan=2 colspan=1>90.8</td><td rowspan=2 colspan=2>1.24</td></tr><tr></tr><tr><td rowspan=1 colspan=1>PPU</td><td rowspan=1 colspan=1>247</td><td rowspan=1 colspan=2>1.21</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>CV (%)</td></tr><tr><td rowspan=1 colspan=1>HS1</td><td rowspan=1 colspan=1>8.58</td><td rowspan=1 colspan=2>2.71</td></tr><tr><td rowspan=1 colspan=1>HS2</td><td rowspan=1 colspan=1>17.4</td><td rowspan=1 colspan=2>1.16</td></tr><tr><td rowspan=1 colspan=1>HS3</td><td rowspan=1 colspan=1>476</td><td rowspan=1 colspan=2>0.64</td></tr><tr><td rowspan=1 colspan=1>PNU</td><td rowspan=1 colspan=1>91.4</td><td rowspan=1 colspan=2>0.58</td></tr><tr><td rowspan=1 colspan=1>PPU</td><td rowspan=1 colspan=1>249</td><td rowspan=1 colspan=2>0.57</td></tr><tr><td rowspan=1 colspan=4>Intermediate (Between Run Precision)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>CV (%)</td></tr><tr><td rowspan=1 colspan=1>HS1</td><td rowspan=1 colspan=1>8.58</td><td rowspan=1 colspan=2>3.20</td></tr><tr><td rowspan=1 colspan=1>HS2</td><td rowspan=1 colspan=1>17.4</td><td rowspan=1 colspan=2>1.65</td></tr><tr><td rowspan=1 colspan=1>HS3</td><td rowspan=1 colspan=1>476</td><td rowspan=1 colspan=2>1.09</td></tr><tr><td rowspan=1 colspan=1>PNU</td><td rowspan=1 colspan=1>91.4</td><td rowspan=1 colspan=2>1.15</td></tr><tr><td rowspan=1 colspan=1>PPU</td><td rowspan=1 colspan=1>249</td><td rowspan=1 colspan=2>1.07</td></tr></table>

# Glucose HK Gen. 3 Stat Assay

Substantial equivalence comparison

<table><tr><td rowspan=1 colspan=1>Compal sul</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=7>COBAS INTEGRA Glucose Gen. 3AssaySerum/Plasma Application</td><td rowspan=1 colspan=3>Predicate Device: COBASINTEGRA Glucose Gen. 3 AssaySerum/Plasma Application(K061048)</td></tr><tr><td rowspan=13 colspan=1>Precision - CSF</td><td rowspan=1 colspan=7>CSF - Regular Application:Repeatability (Within-Run Precision)</td><td rowspan=13 colspan=3>CSF - Regular Application:Within-Run PrecisionSample    Mean    CV (%)(mg/dL)Level I 57.7         1.13Level II168          1.49</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=4>−</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=2 colspan=1>Level I</td><td rowspan=2 colspan=1>57.7</td><td rowspan=2 colspan=1>1.13</td><td rowspan=2 colspan=2>−</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=2 colspan=1>Level I</td><td rowspan=2 colspan=1>57.7</td></tr><tr><td rowspan=1 colspan=3></td></tr><tr><td rowspan=2 colspan=1>Level II</td><td rowspan=2 colspan=1>168</td><td rowspan=2 colspan=1>1.49</td><td rowspan=2 colspan=2>−</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=2 colspan=1>Level II</td><td rowspan=2 colspan=1>168</td></tr><tr><td rowspan=1 colspan=2></td><td></td></tr><tr><td rowspan=7 colspan=7>CSF - STAT Application:Repeatability (Within-Run Precision)Sample    Mean    CV (%)(mg/dL)CSF 1   39.6         0.63CSF 2   283          0.39CSF 3   517          0.51PNU    92.4         0.53PlusPPU     240          0.43Plus</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>CSF 1</td><td rowspan=1 colspan=1>39.6</td><td rowspan=1 colspan=1>0.63</td></tr><tr><td rowspan=1 colspan=1>CSF 2</td><td rowspan=1 colspan=1>283</td><td rowspan=1 colspan=1>0.39</td></tr><tr><td rowspan=1 colspan=1>CSF 3</td><td rowspan=1 colspan=1>517</td><td rowspan=1 colspan=1>0.51</td></tr><tr><td rowspan=1 colspan=1>PNUPlus</td><td rowspan=1 colspan=1>92.4</td><td rowspan=1 colspan=1>0.53</td></tr><tr><td rowspan=1 colspan=1>PPUPlus</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.43</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSensitivity</td><td rowspan=1 colspan=7>Lower Limits of Measurement:Limit of Blank = 2.16 mg/dLLimit of Detection = 4.32 mg/dL</td><td rowspan=1 colspan=3>Lower Detection Limit:2.16 mg/dL</td></tr></table>

# Glucose HK Gen. 3 Stat Assay

Substantial equivalence

<table><tr><td>comparison Feature</td><td>COBAS INTEGRA Glucose Gen. 3 Assay Serum/Plasma Application</td><td>Predicate Device: COBAS INTEGRA Glucose Gen. 3 Assay Serüm/Plasma Application (K061048)</td></tr><tr><td rowspan="5">Limitations- Interference</td><td>Icterus - No significant interference up to an I index of 60 (approximate concentration of conjugated and unconjugated bilirubin: 60 mg/dL or 1026 umol/L)*</td><td>Same</td></tr><tr><td>Hemolysis - No significant interference up to an H index of 1200 (approximate hemoglobin concentration: 1200 mg/dL or 744 umol/L)*</td><td>Same</td></tr><tr><td>Lipemia  No significant interference up to an L index of 1900. There is a poor correlation between the L index (corresponds to turbidity) and the triglycerides concentration.*</td><td>Same</td></tr><tr><td>Other  In very rare cases gammopathy, in particular type IgM (Waldenstrom&#x27;s macroglobulinemia), may cause unreliable results.</td><td>Same</td></tr><tr><td>Drugs - No interference was found at therapeutic concentrations using common drug panels. *measured at a glucose concentrations of</td><td>Not Specified</td></tr></table>

Substantial equivalencecomparison

<table><tr><td>Feature Expected Values</td><td>COBAS INTEGRA Glucose Gen. 3 Assay Serum/Plasma Application Plasma</td><td>Predicate Device: COBAS INTEGRA Glucose Gen. 3 Assay Serum/Plasma Application (K061048) Plasma</td></tr><tr><td rowspan="2"></td><td>Fasting: 74 - 109 mg/dL (Per Thomas L. Blutglucose. In: Thomas L, ed. Labor und Diagnose, 6th ed. Frankfurt/Main: TH-Books, 2005:193-199.) Urine 1 morning: 6 - 20 mg/dL 24-h urine: 6 - 17 mg/dL (average of 1350 mL urine/24 h) acc. to Tietz: Serum,Plasma</td><td>Fasting: 70 - 115 mg/dL (Per Thomas L, ed. Labor und Diagnose, 4 ed. Marburg: Die medizinische Verlagsgesellschaft 1992.) Same Same</td></tr><tr><td>Adults: 74 - 106 mg/dL 60-90 years: 82 - 115 mg/dL . &gt;90 years: 75 - 121 mg/dL Children: 60 - 100 mg/dL Neonates (1 day): 40 - 60 mg/dL Neonates (&gt;1 day): 50 - 80 mg/dL Urine 24-h urine: &lt;0.5 g/24 h Random Urine: 1 - 15 mg/dL</td><td>Same</td></tr><tr><td>Method Comparison - Serum n=79</td><td colspan="2">Glucose values for human serum samples obtained on a COBAS INTEGRA 800 analyzer with the COBAS INTEGRA Glucose HK Gen. 3 reagent were compared to those determined on the same analyzer with the same reagent, but with the Stat application. Passing Bablok Linear Regression y=0.997x + 0.033 mmol/L y=0.997x + 0.032 mmol/L τ =0.999 r=1.00 SD (md 95) = 0.067 Sy.x = 0.032</td></tr></table>

# Glucose HK Gen. 3 Stat Assay

Substantial equivalencecomparison   

<table><tr><td>Feature</td><td>COBAS INTEGRA Glucose Gen. 3 Assay Serum/Plasma Application</td><td>Predicate Device: COBAS INTEGRA Glucose Gen. 3 Assay Serum/Plasma Application (K061048)</td></tr><tr><td rowspan="2">Method Comparison - Urine</td><td colspan="2">Glucose values for human urine samples obtained on a COBAS INTEGRA 800 analyzer with the COBAS INTEGRA Glucose HK Gen. 3 reagent were compared to those determined on the same analyzer with the same reagent, but with the Stat application.</td></tr><tr><td>n=50 Passing Bablok y=1.00x + 0.002 mmol/L τ = 0.996 r=1.00 SD (md 95) = 0.082</td><td>Linear Regression y=1.00x + 0.003 mmol/L Sy.x = 0.041</td></tr></table>

# DEC 4 2009

Roche Diagnostics c/o Kathie J Goodwin $\cdot$ Regulatory Affairs Consultant 9115 Hague Road, Po Box 50416 Indianapolis, IN 46250

Re: k092603 Trade/Device Name: Cobas Integra Glucose Hk Gen 3 Assay Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system. Regulatory Class: II Product Code: CFR Dated: November 3, 2009 Received: November 5, 2009

Dear: Ms. Goodwin:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to n and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with allthe Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450.Als0, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97. For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/96ee8583fe2b4eb87ba5e314803349f0d838d5a0862042787ad04adc121b2619.jpg)

Courtney C. Harper, Ph.D..   
Directr   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indications for Use Form

510k) Number (ikown): K093003

Device Name: COBAS INTEGRA Glucose HK Gen. 3 Assay

Indications for Use:

In vitro test for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid (CSF).

Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia and pancreatic islet cell tumors.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/f633eed0b039ae20176638fd4a5f00abfce03b21976354ae8460e401a782d081.jpg)

Division Signtoff   
Office of In Vitro Diagnostic Device   
Evaluation and Safety